rt-PA

DRUG16 trials

Sponsors

Boehringer Ingelheim, Beijing Chao Yang Hospital, University of Cincinnati, Centre Hospitalier du Centre du Valais, Johns Hopkins University

Conditions

Acute Ischemic StrokeArgatroban, Rt-PABrain InfarctionCerebral ArteryHypertensive Intracerebral HemorrhageIntracerebral HemorrhageIschemic StrokeLacunar Stroke

Phase 1

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

RecruitingNCT06663631

Capital Medical UniversityAcute Ischemic Stroke

Start: 2024-11-09End: 2025-02-28Target: 32Updated: 2024-12-20

Phase 2

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

CompletedNCT00894803

University of CincinnatiBrain Infarction, Ischemic Stroke, Stroke

Start: 2009-07-31End: 2012-12-31Updated: 2014-04-17

Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion

WithdrawnNCT02338466

University Hospital Center of MartiniqueCerebral Artery, Nervous System Disorders

Start: 2016-07-31End: 2018-09-30Updated: 2018-06-21

Dose-effect Relationship of Rt-PA on ICH Evacuation

Tongji HospitalHypertensive Intracerebral Hemorrhage

Start: 2015-06-30End: 2018-06-30Target: 108Updated: 2015-06-16

Phase 3

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

CompletedNCT00148460

Boehringer IngelheimMyocardial Infarction

Start: 2001-03-31End: 2006-02-28Target: 270Updated: 2013-10-29

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

CompletedNCT01827046

Johns Hopkins UniversityIntracerebral Hemorrhage

Start: 2013-12-30End: 2018-09-30Updated: 2019-09-27

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

CompletedNCT04797013

Beijing Tiantan HospitalAcute Ischemic Stroke

Start: 2021-06-12End: 2022-07-15Updated: 2023-01-17

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

CompletedNCT05700591

Tasly Biopharmaceuticals Co., Ltd.Acute Ischemic Stroke

Start: 2023-01-29End: 2024-03-14Updated: 2024-07-26

Phase 4

Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China

CompletedNCT00781378

Beijing Chao Yang HospitalPulmonary Embolism, Thromboembolism

Start: 2002-06-30End: 2006-02-28Updated: 2008-10-29

Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA

Centre Hospitalier du Centre du ValaisMalfunction; Catheter, Mechanical Complication of Hemodialysis Catheter, Thrombosis

Start: 2011-01-31End: 2012-11-30Target: 240Updated: 2012-08-22

Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）

TerminatedNCT03506009

Hui-Sheng ChenArgatroban, Rt-PA

Start: 2018-07-11End: 2018-11-13Updated: 2018-11-14

Argatroban Plus R-tPA for Acute Ischemic Stroke

CompletedNCT03740958

General Hospital of Shenyang Military RegionStroke

Start: 2018-12-21End: 2022-01-30Updated: 2022-02-22

Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial

RecruitingNCT07111559

Nippon Medical SchoolIschemic Stroke, Lacunar Stroke, Stroke

Start: 2025-08-01End: 2029-03-31Target: 500Updated: 2026-02-03

Unknown Phase

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

CompletedNCT05395351

Boehringer IngelheimStroke

Start: 2022-11-30End: 2023-03-28Updated: 2024-12-20

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

CompletedNCT05395338

Boehringer IngelheimStroke

Start: 2022-04-12End: 2022-11-30Updated: 2024-10-16

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

CompletedNCT05401149

Boehringer IngelheimStroke

Start: 2022-07-18End: 2022-12-14Updated: 2024-10-17

Related Papers

Circadian Rhythm and Efficacy of Argatroban in Ischemic Stroke with Alteplase: A Post Hoc Analysis of the ARAIS Trial.

2026-02-12

Intracerebral haemorrhage laterality and associations with mood and pain: a MISTIE III substudy.

2025-12-23

Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial.

2025-10-271 citations

Efficacy of argatroban plus alteplase according to time from onset to thrombolysis in acute ischemic stroke: a prespecified post-hoc analysis of the ARAIS trial

Frontiers in Neurology2025-06-25

Effectiveness of intravenous recombinant plasminogen activator treatment in Chinese patients with acute ischaemic stroke aged over 80 years: a retrospective cohort study

Stroke and Vascular Neurology2025-04-30

Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.

2024-11-2919 citations

In-hospital outcomes of intravenous recombinant tissue plasminogen activator treatment for acute ischemic stroke in patients aged >80 years: Findings from the Chinese Stroke Center Alliance.

2024-10-28

Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia

Journal of the American Heart Association2024-10-112 citations

RhPro-UK in acute ischemic stroke within 4.5 h of stroke onset trial-2 (the PROST-2 study): Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial

International Journal of Stroke2024-06-224 citations

Does stereotactic thrombolysis with alteplase for intracerebral haemorrhage alter intraventricular haematoma volume? A secondary analysis of the MISTIE-III trial

Journal of Neurology Neurosurgery & Psychiatry2024-04-262 citations

Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation: Bayesian Reanalysis of a Randomized Controlled Trial.

2023-09-084 citations

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial

Stroke and Vascular Neurology2023-05-2914 citations

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.

2023-02-09198 citations

Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke

JAMA2023-02-0956 citations

Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials.

2021-12-228 citations

Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design

Stroke and Vascular Neurology2021-08-2613 citations

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.

2019-02-07610 citations

Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.

2013-07-2570 citations

Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.

2009-09-09190 citations